Bacteria: Gram-negative

Morganella morganii

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A urease-producing Gram-negative rod causing opportunistic and healthcare-associated infection.

Infections

Catheter-associated urinary tract infection, wound and bloodstream infection.

Signs and symptoms

Urinary infection, often in older adults with long-term catheters: painful urination, flank pain, fever or catheter blockage. Wound and soft-tissue infection, including diabetic foot ulcers and surgical wounds: redness, swelling and foul-smelling drainage. Bloodstream infection: fever and chills.

Antibiotic and antimicrobial resistance

Chromosomal AmpC (AmpC); intrinsically resistant to nitrofurantoin and colistin.

Treatment considerations

Guided by susceptibility testing. IDSA guidance places Morganella, like Serratia, at lower risk of AmpC induction during therapy. Intrinsically resistant to colistin and nitrofurantoin.

Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Healthcare-associated infections: diseases and organisms.
  2. CDC. ESBL-producing Enterobacterales.
  3. CDC. Carbapenem-resistant Enterobacterales (CRE).
  4. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  5. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.